FDA Advisory Committee Recommends Compounding of BPC-157 Peptide

The Pharmacy Compounding Advisory Committee voted 8-6 to recommend that compounding pharmacies be allowed to produce BPC-157, a peptide that has gained popularity for its purported healing properties. The recommendation comes despite concerns from FDA researchers regarding the lack of human safety data and the peptide's absence from the standard FDA drug approval process. Supporters of the recommendation, including committee member Kris Wusterhausen, argue that allowing regulated access to BPC-157 could prevent consumers from sourcing it from unverified online vendors. However, some committee members, including Brian Lee, expressed concerns that this could mislead the public into believing the peptide has FDA approval. The committee also recommended other peptides, including TB-500 and KPV, which could represent significant market opportunities for compounding pharmacies and telehealth companies.